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Abstract
Background: Coronaviruses such as severe acute respiratory syndrome (SARS) coronavirus (SCoV) and mouse hepatitis virus
A59 (MHV-A59) have evolved strategies to disable the innate immune system for productive replication and spread of
infection. We have previously shown that papain-like protease domain 2 (PLP2), a catalytic domain of the nonstructural
protein 3 (nsp3) of MHV-A59, encodes a deubiquitinase (DUB) and inactivates IFN regulatory factor 3 (IRF3) thereby the type
I interferon (IFN) response.
Principal Findings: Here we provide further evidence that PLP2 may also target TANK-binding kinase-1 (TBK1), the
upstream kinase of IRF3 in the IFN signaling pathway. Overexpression experiments showed that PLP2 deubiquitinated TBK1
and reduced its kinase activity, hence inhibited IFN-b reporter activity. Albeit promiscuous in deubiquitinating cellular
proteins, PLP2 inactivated TBK1 and IFN-b response in TNF receptor associated factor 3 (TRAF3) deficient cells, suggesting
that targeting TBK1 would be sufficient for PLP2 to inhibit IRF3 activation. This notion was further supported by in vitro
kinase assays, in which prior treatment of TBK1 with PLP2 inhibited its kinase activity to phosphorylate IRF3. Intriguing
enough, results of PLP2 overexpression system and MHV-A59 infection system proved that PLP2 formed an inactive
complex with TBK1 and IRF3 in the cytoplasm and the presence of PLP2 stabilized the hypo-phosphorylated IRF3-TBK1
complex in a dose-dependent manner.
Conclusions: These results suggest that PLP2 not only inactivates TBK1, but also prevents IRF3 nuclear translocation hence
inhibits IFN transcription activation. Identification of the conserved DUB activity of PLP2 in suppression of IFN signaling
would provide a useful clue to the development of therapeutics against coronaviruses infection.
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Introduction
The innate immune system senses microbial infection and
initiates counteractive response through evolutionary conserved
pattern recognition receptors (PRRs) [1–3]. At least three classes of
PRRs have been identified, designated Toll-like receptors (TLRs),
retinoic acid-inducible gene I (RIG-I)-like helicases (RLHs) and
nucleotide-oligomerization domain (NOD)-like receptors (NLRs).
In response to virus infection, these receptors detect viral
pathogen-associated molecular patterns (PAMPs) to elicit produc-
tion of type I interferons (IFNs) and pro-inflammatory cytokines
[4,5]. These sensors, either on cell surface or in cytoplasm, usually
require different adaptor molecules, such as TRIF, MyD88 or
Cardif [6–9], for activation of two inhibitor of NF-kB kinase (IKK)
homologues, namely TANK-binding kinase-1 (TBK1) and IKKe
[10,11]. Recent studies also indicate that a common TNF receptor
associated factor 3 (TRAF3) adaptor complex is essential in the
activation of TBK1 and IKKe for the production of IFNs [12,13].
Activated TBK1 phosphorylates IFN regulatory factor 3 (IRF3),
which then translocates to the nucleus and initiates transcription
activation of IFN genes [14]. Secreted IFN further activates its
down-stream signaling pathway, including phosphorylation of the
tyrosine residues of the Janus kinase (JAK) and signal transducers
and activators of transcription (STAT) proteins, to initiate anti-
viral related genes expression [15].
Ubiquitination is to covalently conjugate the ubiquitin mole-
cule(s) to the target proteins. There are seven lysine (K) residues
within ubiquitin, and ubiquitination chains involving these
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17192different K play important roles in regulation of diverse fates of
proteins. For example, K48-linked poly-ubiquitination usually
leads to 26S proteasomal degradation of the modified proteins,
whereas K63-linked ubiquitination often involves in signaling
activation of numerous molecules. A large body of evidence has
indicated that ubiquitination is critical for IFN induction. K63-
linked ubiquitination of RIG-I by an E3 ubiquitin ligase TRIM25
is necessary and sufficient to trigger the downstream signaling
cascade to produce IFN [16]. K63-linked autoubiquitination of
TRAF3, an E3 ubiquitin ligase per se, is required in the activation
of IFN signaling [13,17]. TANK (TRAF family member-
associated NF-kB activator), a scaffold protein of TBK1 and
IKKe, is also reported to be poly-ubiquitinated through TRAF3-
and Ubc13-dependent K63 linkage [18]. A recent study identifies
that another E3 ligase, Nrdp1, can enhance the K63-linked
ubiquitination and activation of TBK1 [19]. To keep the IFN
activation in balance, there are a set of different cellular
deubiquitinases, such as A20, CYLD, YopJ and deubiquitinating
enzyme A (DUBA), that maintain the activation homeostasis of
each essential checkpoint factors aforementioned [17,20–23].
However, making the situation more complicated, ubiquitination
does not always provide activation signal for IFN induction. For
example, RBCK1, TRIM21 and a Cullin-based ubiquitin ligase
are identified to induce poly-ubiquitination of IRF3, which leads
to proteasomal degradation and inactivation of IRF3 [24–26].
Numerous viruses can precisely target the innate immune
signaling pathway for productive replication and spreading.
Clinical evidence has revealed that SARS coronavirus (SCoV), a
highly pathologic Class II coronavirus, induces very low levels of
IFN, indicating an evasion mechanism intrinsic to this family of
viruses from the innate immune surveillance [27–29]. One
possible mechanism is that the papain-like protease (PLpro)
domain of the nonstructural protein 3 (nsp3) of SCoV can serve
as a potent IFN antagonist by inhibiting the phosphorylation and
nuclear translocation of IRF3 [30]. Our previous study further
demonstrates that PLP2 domain of nsp3 of mouse hepatitis virus
A59 (MHV-A59) encodes a deubiquitinase (DUB) domain
conserved for the Class II coronaviruses, that can effectively
deubiquinate IRF3 and prevent it from phosphorylation and
nuclear translocation [31]. In this study, we further demonstrate
that, in addition to IRF3, TBK1 is also targeted by PLP2 of
MHV-A59. PLP2 not only deubiquitinates TBK1 and inactivates
its kinase activity to phosphorylate IRF3, but also delays the
dissociation of IRF3 from TBK1, thereby effectively attenuates
IFN induction.
Results
The PLP2 domain of MHV-A59 nsp3 deubiquitinates TBK1
We have previously reported that PLP2 of MHV-A59 nsp3
deubiquitinated and inactivated IRF3 to inhibit cellular IFN
induction [31]. Because multiple regulatory molecules upstream of
IRF3 in the IFN pathway are involved in ubiquitination and
deubiquitination, especially due to the fact that TBK1 can be
ubiquitinated by a cellular E3 ligase Nrdp1 [19], we were tempted
to ask whether PLP2 could target TBK1 to suppress the antiviral
IFN signaling. Ubiquitination of TBK1 seemed an efficient tactic
to activate IFN response because the endogenous TBK1 was K63-
linked poly-ubiquitinated at 8 h post Sendai virus (SeV) infection
(Fig. 1A, top panel) and accompanied with phosphorylation of
IRF3 and STAT1, the indications of the IFN production (Fig. 1A,
panels 4–5). On the other hand, co-immunoprecipitation exper-
iments showed that PLP2 and its enzyme-dead mutant PLP2-
C106A [31] formed a complex with TBK1 (Fig. 1B). Further
ubiquitination assay demonstrated that overexpressed TBK1
became K63-linked poly-ubiquitinated, which was effectively
inhibited by a co-expressed PLP2 but not PLP2-C106A (Fig. 1C).
This was also supported by result of ubiquitination assay in MHV-
A59 infection system. Using SeV as a control, MHV-A59 infection
resulted in no marked K63-linked ubiquitination of TBK1 in
mouse embryonic fibroblast (MEF) cells (Fig. S1). Moreover, the
luciferase reporter experiments showed that TBK1-driven IFN-b
promoter activities were reduced by PLP2 in a dose-dependent
manner, but not by PLP2-C106A (Fig. 1D). These results
indicated that PLP2 retarded the activation of TBK1 through its
DUB activity.
Targeting TBK1 by PLP2 is sufficient to block IFN
induction
PLP2 is a potent deubiquitinase that has a broad spectrum of
cellular substrates as shown in Fig. 1C as well as in our previous
report [31]. To exclude the potential non-specific effect by PLP2
on IFN induction, especially on those regulatory molecules
upstream of TBK1 in the IFN signaling pathway, we firstly tested
whether PLP2 would still inhibit TBK1-driven IFN-b promoter
activities in Traf3
2/2 MEF cells. Overexpression of TBK1 in
Traf3
2/2 cells could still efficiently activate IFN-b promoter,
suggesting that autonomously activated TBK1 could bypass the
requirement of the upstream receptor-adaptors signaling. TBK1-
driven IFN-b reporter activity, however, was effectively inhibited
by the co-expressed PLP2 but not PLP2-C106A (Fig. 2A).
Decreased IFN-b promoter activities correlated well to the
reduced poly-ubiquitination level of TBK1 by PLP2 in Traf3
2/2
cells (Fig. 2B). These results therefore suggested that deubiquitina-
tion of TBK1 and/or IRF3 by PLP2 would be sufficient to reduce
IFN-b promoter activities.
Paradoxically, PLP2 can also reduce the ubiquitination level of
IRF3 to diminish its ability in IFN induction [31]. Because IRF3
activation requires TBK1 [11], it is therefore desirable to delineate
which factor, TBK1, IRF3 or both, is the primary target for PLP2.
PLP2 action on IRF3 was apparently independent of TBK1, as
PLP2 but not PLP2-C106A specifically inhibited IRF3-driven
IFN-b promoter activities in Tbk1
2/2 cells (Fig. 2C). This was also
correlated with the reduced poly-ubiquitination level of IRF3 by
PLP2 in Tbk1
2/2 MEF cells (Fig. 2D). The apparent explanation
for these results would be an advantageous strategy for coronavirus
to evade the anti-viral line of defense through destructing multiple
innate signaling components, e.g., TBK1 and IRF3. To determine
which step of deubiquitination is causative, we first measured
whether the kinase activities of TBK1 would be directly affected
by PLP2 by in vitro kinase assays. Flag-TBK1 ectopically expressed
in HEK293T cells in the presence of co-expressed PLP2 (WT or
C106A) was affinity purified. The subsequent measurement of
kinase activities using the purified C-terminal domain of IRF3
(GST-IRF3131–426) as substrate showed that the presence of PLP2
but not PLP2-C106A robustly inhibited the kinase activity of
TBK1 in its autophosphorylation and IRF3 phosphorylation
(Fig. 3A). The kinase activity of Flag-TBK1 immuno-purified from
Traf3
2/2 MEF cells exhibited the similar dependence on PLP2
(Fig. 3B). Therefore, deubiquitinating TBK1 was sufficient for
PLP2 to down-regulate IRF3 phosphorylation. Furthermore, we
mixed the recombinant human TBK1 purified from insect cells
with PLP2 (WT or C106A) immunopurified from HEK293T cells.
Surprising enough, the recombinant TBK1 purified from insect
cells was already ubiquitinated (Fig. 3C, the third panel),
suggesting a conserved post-translational modification of TBK1.
Pre-incubation of PLP2 reduced ubiquitination level of TBK1 and
remarkably inhibited its kinase activity on IRF3 (Fig. 3C, the
PLP2 Targets TBK1 to Inhibit Type I IFN Response
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reaction did not interfere with TBK1 in phosphorylating IRF3.
These results therefore suggested that deubiquitination of TBK1
by PLP2 would be sufficient to suppress type I IFN induction.
PLP2 stabilizes the inactive TBK1-IRF3 complex in the
cytoplasm
IRF3 is directly phosphorylated by TBK1 for transcription
activation [11]. We have previously reported that IRF3 forms a
Figure 1. K63-linked ubiquitination involved in the process of TBK1 activation could be inhibited by MHV-A59 PLP2. (A) SeV infection
induces K63-linked polyubiquitination of TBK1. HEK293T cells in 60 mm plates were transiently transfected with 3.6 mg HA-tagged ubiquitin K63 (HA-
Ub-K63) expressing plasmids. At 24 h post transfection, cells were infected with SeV (HA titer 1:25). At indicated time post infection, ubiquitination
status of the endogenous TBK1 was immunoblotted with anti-HA antibody after immunoprecipitated by anti-TBK1 antibody (3 mg, IP: TBK1). TBK1
was not apparently degraded after viral infection as similar amounts of TBK1 were immunoabsorbed on beads (IB: TBK1). The whole cell lysates (WCL)
was immunoblotted with anti-HA antibody for ubiquitin expression and massive cellular ubiquitination (HA), and anti-b-actin antibody for input.
Immunobloting with phosphor-IRF3 and phosphor-STAT1 specific antibodies showed activation of TBK1 after viral infection for time indicated (p-
IRF3, p-STAT1). (B) PLP2 associates with TBK1. HEK293T cells transiently expressing Flag-tagged TBK1 (Flag-TBK1) and Myc-tagged PLP2 (Myc-PLP2,
WT or C106A) were lysed and immuoprecipitated with anti-Flag or -Myc antibodies. The immunoprecipitates were SDS-PAGE resolved and
immunoblotted with antibody indicated. Mouse IgG was used as IP controls for Myc or Flag antibodies. (C) PLP2 deconjugates K63-linked
polyubiquitin chains on TBK1. HEK293T cells (in 35 mm plates) transiently transfected with plasmids (800 ng each) encoding Flag-TBK1, HA-Ub-K63 or
Myc-PLP2 (WT or C106A) for 24 h. Whole cell lysates were immunoprecipitated with anti-Flag antibody (1 mg) and SDS-PAGE resolved precipitates
were immunoblotted with anti-HA or -Flag antibodies, respectively (IP: Flag). The expression of the epitope-tagged exogenous proteins was verified
with the indicated antibodies (WCL). (D) PLP2 inhibits TBK1-driven IFN-b promoter activities. IFN-b-Luc promoter reporter (50 ng) and pCMV-Renilla
internal control (15 ng) plasmids were co-transfected with Myc-TBK1 (100 ng) and Myc-PLP2 (WT or C106A, in three doses of 50, 100 and 200 ng) into
HEK293T cells (24 well plates). Dual luciferase activities were measured and normalized to Renilla luciferase activities 24 h post transfection. Fold
activation over the sham vector (pCMV-Myc) was averaged from three independent experiments (mean6SD). Expression of the exogenous epitope-
tagged proteins was verified with the indicated antibodies (WCL). Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0017192.g001
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PLP2 also formed a complex with TBK1. Therefore a tripartite
complex containing TBK1/IRF3/PLP2 would exist in cells after
infection of MHV-A59. To test this hypothesis, we co-expressed a
fixed amount of Flag-IRF3 and Myc-TBK1 with elevated levels of
Myc-PLP2 in HEK293T cells (Fig. 4A, WCL panel). Co-immuno-
precipitation using Flag antibody showed that these three compo-
nents formed an immuno-complex, and increasing amounts of Myc-
PLP2 recruited more Myc-TBK1 into the complex (Fig. 4A, top two
panels). Intriguing enough, anti-phospho-IRF3 antibody detected a
decreasing phosphorylation of IRF3 (Fig. 4A, the fifth panel). It is
therefore reasonable to speculate that the presence of PLP2
deubiquitinated and inactivated TBK1, which consequently deceler-
ated the phosphorylation of IRF3 in the complex. Hypo-phosphor-
ylated IRF3 would have a higher affinity to TBK1 as evidenced by
more TBK1 associated with unphosphorylated IRF3. The presence
of PLP2 likely stabilized the complex of TBK1 and IRF3 by
inhibiting the dissociation of IRF3 from TBK1. To clarify if there
would be any artifact in the abovementioned co-immunoprecipita-
tion, we then mixed the enzyme and the substrate in trans.
Immunopurified Flag-TBK1 co-expressing with Myc-PLP2 (WT or
C106A) was incubated with purified GST-IRF3131–426.I m m u n o p r e -
cipitation with Flag antibody (Fig. 4B) demonstrated that GST-
IRF3131–426 interacted with hypo-ubiquitinated TBK1 (coexpressed
with wild type PLP2, lane 2) more efficiently than with hyper-
ubiquitinated TBK1 (coexpressed with PLP2-C106A, lane 3).
Similarly, if immunopurified Flag-IRF3 co-expressing with Myc-
PLP2 (WT or C106A) was incubated with the recombinant TBK1
(Fig. 4C), TBK1 had a tendency to interact with hypo-ubiquitinated
(coexpressed with wild type PLP2, lane 2) more efficiently than
with hyper-ubiquitinated IRF3 (coexpressed with PLP2-C106A,
lane 3).
Figure 2. PLP2 inhibits IFN-b signaling by deubiquitinating both TBK1 and IRF3. (A) PLP2 inhibits TBK1-driven IFN-b promoter activities in
Traf3
2/2 MEF cells. Luciferase assays were performed as in Fig. 1D except that Traf3
2/2 MEF cells (in 24-well plates) were transfected with different
amount ofeach plasmids:150 ngforIFN-b-Luc reporter,50 ngforRenilla,200 ngfor Myc-TBK1 andincreasingdoses(100,200and400 ng)forMyc-PLP2
(WT or C106A). Fold activation over the sham vector (pCMV-Myc) was averaged from three independent experiments (mean6SD). (B)P L P 2
deubiquitinates TBK1 in Traf3
2/2 MEF cells. Experiments were performed as in Fig. 1C except that Traf3
2/2 MEF cells (in 10 cm plates) were transfected
with 8 mg of each plasmid for Flag-TBK1, HA-Ub or Myc-PLP2 (WT or C106A) for 36 h before immunoprecipitation. (C) PLP2 inhibits IRF3-driven IFN-b
promoter activities in Tbk1
2/2 cells. Experiments were carried out as in (A) except that plasmids expressing Flag-IRF3 and Myc-PLP2 (WT or C106A) were
co-transfected into Tbk1
2/2 cells. (D) PLP2 deubiquitinates IRF3 in Tbk1
2/2 cells. Experiments were performed as in (B) except that Tbk1
2/2 MEF cells
were transfected with Flag-IRF3, HA-Ub and Myc-PLP2 (WT or C106A). Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0017192.g002
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p r e s s e dP L P 2d o m a i nw i t hT B K 1a n dI R F 3 .T oi n v e s t i g a t e
whether such a complex existed in MHV-A59 infected cells, we
used a MHV-A59 permissive cell line 17Cl-1 and an engineered
HEK293T cell line stably expressing MHV-A59 receptor
(HEK293T-mCEACAM-1) to repeat the experiment mentioned
above. Immunoblotting showed that antiserum directed against
PLP2 domain could detect a 60 kD protein band as early as 2 h
post MHV-A59 infection, indicating most likely the appearance
o fac l e a v a g ep r o d u c to fn s p 3t h a tc o n t a i n sP L P 2d o m a i n
(Fig. 5A). To address if this PLP2 domain containing protein was
also in the complex of TBK1-IRF3, we then overexpressed Flag-
IRF3 in HEK293T-mCEACAM-1 cells or 17Cl-1 cells before
MHV-A59 infection. Co-immunoprecipitation using Flag anti-
body yielded the results of Flag-IRF3 associating with the
endogenous TBK1 and a viral protein positive for PLP2
antiserum in HEK293T-mCEACAM1 cells (Fig. 5B) and
17C1-l cells (Fig. 5C). Intriguing enough, although overexpressed
IRF3 could recruit TBK1 (Fig. 5B and C, top panel lane 2),
infection with MHV-A59 led to enhanced association of
Figure 3. PLP2 inhibits IFN signaling by inactivating the kinase activity of TBK1. (A) PLP2 inhibits IRF3 phosphorylation by inactivating
TBK1. Plasmids (800 ng) expressing Flag-TBK1 (WT or kinase dead mutant K38A) and Myc-PLP2 (WT or C106A) were co-expressed in HEK293T cells (in
35 mm plates). At 36 h post transfection, cells were lysed and Flag-TBK1 was immunoprecipitated with anti-Flag antibody. Immunoabsorbed Flag-
TBK1 was incubation with recombinant GST-IRF3131–426 (1 mg) and c-
32P-ATP at 25uC for 30 min. Phosphorylation of proteins was resolved by SDS-
PAGE and autoradiography. Expression of the exogenous proteins was verified with the indicated antibodies (WCL). (B) PLP2 inhibits TBK1 kinase
activity in Traf3
2/2 MEF cells. The similar in vitro kinase assays were carried out as in (A) except that 8 mg of each plasmid expressing Flag-TBK1(WT or
K38A) and Myc-PLP2 (WT or C106A) were co-transfected into Traf3
2/2 MEF cells (in 10 cm plates). (C) PLP2 inactivates the recombinant TBK1 by
deubiquitination. An equal amount of recombinant TBK1 (500 ng) was incubated with Myc-PLP2 (WT or C106A) immunopurified from HEK293T cells
at 37uC for 2 h. The kinase activities were measured as in (A). The deubiquitination efficiency of TBK1 was examined with anti-ubiquitin antibody and
the amount of Myc-PLP2 (WT or C106A) used in each reaction was measured by anti-Myc antibody. Data are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0017192.g003
Figure 4. PLP2 stabilizes TBK1-IRF3 complex. (A) PLP2 inhibits the phosphorylation of IRF3 by inactivating TBK1 but stabilizes TBK1-IRF3
complex. A fixed amount of plasmids (800 ng each) for expressing Flag-IRF3 and Myc-TBK1, and an increasing amount (200, 400 and 800 ng) of Myc-
PLP2 were co-transfected into HEK293T cells (in 35 mm plates). At 24 h post transfection, cells were lysed and immunoprecipitated with anti-Flag
antibody. TBK1 and PLP2 associated with IRF3 were detected with anti-Myc antibody. Expression levels of the exogenous proteins were verified with
the indicated antibodies. Anti-phosphor-IRF3 antibody was used to detect the activation status of IRF3 (WCL). (B) Hypo-ubiquitinated TBK1 bounds
recombinant IRF3 more efficiently. Flag-TBK1 co-expressed with Myc-PLP2 (WT or C106A) was immuno-purified as in Fig. 3A and incubated with
recombinant GST-IRF3131–426 (2 mg) in 1 mL lysis buffer at 4uC for 4 h. The formed TBK-IRF3 complex was then separated by centrifugation and SDS-
PAGE resolved. The amount of IRF3 and TBK1 was immunoblotted with anti-GST and anti-Flag antibodies, respectively (IP: Flag). Expression of the
exogenous proteins was verified with the indicated antibodies (WCL). (C) Hypo-ubiquitinated IRF3 interacts with TBK1 more efficiently. Flag-IRF3 in
the presence of Myc-PLP2 (WT or C106A) was immunoprecipitated with anti-Flag antibody and each precipitate was incubated with recombinant
human TBK1 as in (B). Pulled-down TBK1 by IRF3 was immunoblotted with anti-TBK1 antibody. Expression of the exogenous proteins was verified
with the indicated antibodies (WCL). Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0017192.g004
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lane 4). These results therefore strongly suggested that PLP2
domain that associated with TBK1/IRF3 complex may contrib-
ute to the suppressed IFN response via inactivation of TBK1/
IRF3 by its DUB activity in MHV-A59 infected cells.
Therefore, by tempering the ubiquitination of both TBK1 and
IRF3, and subsequent phosphorylation of both, PLP2 would
provide a favorable steric conformation for inter-molecular
interaction between inactivated TBK1 and IRF3. Such a stabilized
complex would hinder the nuclear translocation of IRF3, thereby
inhibit IFN induction. These results therefore provided a tentative
model to explain why MHV-A59, in a broader sense for SCoV as
well, fails to provoke robust IFN response either in vivo or in vitro.
Discussion
The innate immune system is programmed to produce the type
I IFN to deter viral infection, and ubiquitination is critically
involved in the signaling process [25,32]. On the other hand,
during host-pathogen co-evolution, viruses have adopted effective
gene programs to evade or subvert the innate immune system of
the host cells [7,25]. For example, the class II coronaviruses may
adopt an unknown mechanism to shield MHV RNA from
detection by intracellular sensor molecules [33,34]. Papain-like
protease of SCoV serves as a deubiquitinating enzyme [35] to
block IRF3-mediated type I IFN induction [30]. This is supported
by our previous work [31] that PLP2 of MHV-A59, a conserved
class II coronavirus family member, can also specifically
deubiquitinate and inhibit IRF3 activation, accountable for viral
inhibition of cellular type I IFN production [36]. Other laboratory
has also reported that MHV-A59 infection may partially limit the
ability of IRF3 to function as a transcription factor [37]. Herein,
we provide additional evidence on how class II coronaviruses
subvert the innate defense. We have found that PLP2 of MHV-
A59 can also target TBK1 to negatively regulate cellular type I
IFN signaling pathway. It is the first evidence, to our best
knowledge, that TBK1 activation is inhibited by a viral
deubiquitinating enzyme.
Figure 5. TBK1, IRF3 and PLP2 domain containing protein co-localize in one complex in MHV-A59 infected cells. (A) PLP2 domain
containing protein is detected at 2 h post MHV-A59 infection. HEK293T-mCEACAM-1 cells or 17Cl-1 cells (in 35 mm plates) were infected with MHV-
A59 (MOI=5) for the time indicated, and cell lysates were immunoblotted with antiserum directed against MHV-A59 PLP2. Cell lysates of HEK293T
ectopically expressing Myc-PLP2 was used as a positive control (lanes 6 and 12). (B) PLP2 containing protein stabilizes TBK1-IRF3 complex in MHV-A59
infected HEK293T-mCEACAM-1 cells. Plasmid encoding Flag-IRF3 or empty vector (1.2 mg) was transfected into HEK293T-mCEACAM-1 cells (in 35 mm
plates). At 24 h post transfection, cells were simultaneously mock infected or infected with MHV-A59 for additional 10 h (MOI=5) before lysed and
immunoprecipitated with anti-Flag antibody. Endogenous TBK1 and PLP2 domain containing protein associated with Flag-IRF3 were immunoblotted
with anti-TBK1 antibody or antiserum against PLP2 domain (IP: Flag). Expression levels of the exogenous proteins were verified with the indicated
antibodies. (C) PLP2 containing protein stabilizes TBK1-IRF3 complex in MHV-A59 infected 17Cl-1 cells. Experiments were carried out as in (B) except
with 17Cl-1 cells that expressing Flag-IRF3. Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0017192.g005
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IRF3 to activate IFN transcription [10,11,14]. Both factors are
ubiquitinated to activate IFN signaling, with Nrdp1 on TBK1
[19], and an unknown E3 ligase on IRF3 [31,36]. Our studies
suggest that deubiquitination of TBK1 and/or IRF3 [31] by the
viral PLP2 effectively reduce phosphorylation of TBK1 and IRF3,
therefore IFN activation. Simultaneously or sequentially targeting
TBK1 and IRF3 would be beneficial to MHV-A59 in spreading
infection through effectively suppressing the type I IFN response.
PLP2 is able to reduce TBK1 ubiquitination as well as its activity
of phosphorylating IRF3 in Traf3
2/2 cells. We therefore tend to
propose that TBK1 is the primary target for PLP2, and
deubiquitination of TBK1 would be sufficient for PLP2 to inhibit
IFN signaling. The conclusion that DUB activity of PLP2 of
coronaviruses antagonizes IFN response is contradicted by a
recent study in which DUB activity of PLP2 of another
coronavirus HCoV-NL63 is not required to inhibit IFN response
[38]. The most pronounced evidence came from the enzymatic
mutants of PLP2 (C1678A and H1836A), which still possess dose-
dependent inhibition of IFN-b promoter activity. This result
indicates a possible catalytic activity-independent mechanism that
acts to inhibit IFN induction by NL63 PLP2. However, in their
study, inhibition by catalytic mutants of PLP2 is reduced
compared to equivalent amounts of wild type PLP2. So, the
possibility still could not be ruled out that enzymatic activity of
PLP2 may also contribute to IFN antagonism. Furthermore, in
their study, limited results proved that these two enzymatic
mutants of PLP2 lost DUB activity completely. The ubiquitination
level in cells expressed PLP2 C1678A seems lower than that in
cells without PLP2. Another explanation would be the apparent
difference of virus strains and host cells that elicit IFN responses.
Restrained by the fact that TBK1 requires IRF3 to transmit
signals, we were unable to delineate whether a reduced IFN
response by PLP2 was due to deubiquitination of TBK1, IRF3, or
both. Identification of the ubiquitin modification site(s) within
TBK1 would help decipher the underlying mechanism.
The finding that PLP2 or PLP2 domain-containing protein
stabilizes the TBK1-IRF3 complex is very intriguing. Most, if not
all, evidences indicate that viruses inhibit type I IFN response
through interfering with the inter-molecular interaction between
IRF3 and TBK1/IKKe, such as VP35 of Ebola virus [39], V
proteins of Paramyxovirus [40] and c34.5 protein of Herpes
simplex virus 1 [41]. This unexpected finding can be explained by
the fact that PLP2 is a deubiquitinase per se. Removing
polyubiquitin chains, possibly subsequent phosphate groups,
would provide a favorable steric interface between TBK1 and
IRF3 that enhances the inter-molecular interaction. Moreover, a
deubiquinated TBK1 by PLP2 loses its kinase activity, thereby
leads to more hypo- or un-phosphorylated IRF3 accumulated.
Therefore, the presence of PLP2 would favor the formation of
more cytosolic TBK1-IRF3 complex. In addition to shutting down
the TBK1-IRF3 activation signaling, PLP2 can also help sequester
IRF3 from nuclear translocation by stabilizing the TBK1-IRF3
complex in the cytosol, as we have observed previously [31]. The
proposed inter-molecular interactions among PLP2, TBK1 and
IRF3 in attenuating IFN signaling has not been able to be
identified in another study [42]. This discrepancy would stem from
the different PLP2 sequences used by two studies, with over 30
amino acids in the C-terminal region of PLP2 being truncated in
the latter work.
In conclusion, MHV-A59 may take advantage of its PLP2 to
negatively regulate the type I IFN signaling via targeting TBK1,
the hub kinase in IFN signaling. As many different coronavirus
proteins have been discovered to target various molecules of innate
immune system [29], DUB activity of PLP2 may be one of the
most effective arsenal for coronavirus to retard and/or escape
from the type I IFN response. Understanding the underlying
spatial and temporal regulation of innate immune response to
MHV-A59 may shed a light on diagnostic and therapeutic
discovery against coronavirus infection.
Materials and Methods
Cells and plasmids
TBK1 and TRAF3 knockout mouse embryonic fibroblast cells
(Tbk1
2/2 and Traf3
2/2 MEF cells), wild-type MEF cells [43,44],
and HEK293T cells (ATCC, USA) were routinely maintained in
DMEM (Hyclone, UT) supplemented with 10% FBS (PAA,
Pasching, Austria) and 1% penicillin and streptomycin (Hyclone,
UT). Cell line 17Cl-1 is a kind gift from Dr K Holmes (University
of Colorado Health Sciences Center, USA). The overexpression
constructs, pCMV-Myc-PLP2, its DUB mutant derivative,
pCMV-Myc-PLP2-C106A, and pFlag-CMV2-IRF3 were de-
scribed previously [31]. To construct bacterial expression vector
pGEX-6P-2-PLP2, the DNA fragment encoding PLP2 was
subcloned in frame into the EcoRI and XhoI sites of pGEX-6P-2
vector (GE Healthcare). Full-length human Tbk1 gene was PCR
subcloned into different pCMV vectors (Clontech) in between SalI
and NotI sites, to generate plasmids of Flag- or Myc-tagged TBK1.
Wild-type ubiquitin expression vector pRK5-HA-Ub and arginine
substitutions of all lysine residues except for position 63 (designated
as Ub-K63) [45], were provided by Dr K Lim (National
Neuroscience Institute, Singapore). Bacterial expression vector,
pGEX-4T-1-IRF3-131C [46], that expressing a GST-tagged C-
terminal domain of IRF3 (GST-IRF3131–426), was kindly provided
by Dr I. Rogatsky (Weill Medical College of Cornell University,
USA). Full-length mouse Ceacam-1 gene was created by PCR and
was subcloned in frame into pBABE-puro vector in between EcoRI
and SalI sites, to generate MHV receptor (MHVR) expression
vector pBABE-puro-mCEACAM-1. To establish cell lines stably
expressing MHVR, HEK293T cells seeded in a 12-well plate were
transfected with 1.6 mg pBABE-puro-mCEACAM-1, and the
stable clone was selected by 20-fold dilution in the presence of
1 mg/mL puromycin.
Antibodies, reagents and virus stock
Antibodies specific to IRF3, ubiquitin, HA and GST were
purchased from Santa Cruz Biotech (Santa Cruz, CA), Flag (M2)
and b-actin from Sigma-Aldrich (St Louis, MO), Myc from
Shanghai Genomics (Shanghai, China), phosphorylated STAT1,
phosphorylated IRF3 and TBK1 were from Cell Signaling Tech
(Beverly, MA). HRP conjugated goat anti-mouse IgG light chain
specific secondary antibody was from Jackson Immunoresearch
(West Grove, PA). Recombinant human TBK1 purified from
baculovirus expression system was purchased from Invitrogen
(Carlsbad, CA). c-
32P- ATP was obtained from FuruiBio (Beijing,
China). All other fine chemicals were from Sigma-Aldrich (St
Louis, MO). Expansion of Sendai virus (SeV) and MHV-A59 and
infection experiments were described previously [31]. The mouse
antiserum against MHV-A59 PLP2 domain was prepared by
CoWin Biotech (Beijing, China) using the full length recombinant
PLP2 as the immunogen.
Transfection, co-immunoprecipitation and luciferase
assays
Transient transfection of HEK293T cells with indicated
plasmids was performed routinely with calcium phosphate
method. Lipofectamine 2000 (Invitrogen) was used to transfect
PLP2 Targets TBK1 to Inhibit Type I IFN Response
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17192plasmids into other cells. For co-immunoprecipitation, cells were
lysed with lysis buffer (25 mM HEPES, pH 7.5, 150 mM NaCl,
1% TritonX-100, 1 mM EDTA, 1 mM PMSF, 10 mM NaF,
1m MN a 3VO4 and 16protease inhibitor cocktail) on ice at 24 h
post transfection. Protein complexes were immunoprecipitated
with indicated antibodies (IP) and separated by SDS-PAGE for
immunoblotting analysis with antibodies (IB) as indicated. To
detect ubiquitination of desired proteins, cells were collected and
first sonicated in the denaturing buffer (lysis buffer plus 1% SDS
and 1% b-mercaptoethanol) followed by boiling for 5 min. The
lysates were then diluted with 10-fold lysis buffer before
immunoprecipitation. IFN-b luciferase reporter assays and statistic
analyses were performed exactly as previously described [31].
RT-PCR
Total RNA was extracted according to manufacturer’s
instruction with Trizol (Invitrogen). RT-PCR was performed
using RT-PCR kit (Promega) according to manufacturer’s manual
with the following primers: mouse b-actin forward, 59-
GTCCCTCACCCTCCCAAAAG-39; mouse b-actin reverse, 59-
GCTGCCTCAACACCTCAACCC-39; SeV N gene forward, 59-
GATCGTTGGGAACTACATCCGAG-39; SeV N gene reverse,
59- GACAGGTAGGTGTCTATGAGGC-39; MHV SM gene
forward (CK4), 59-TCGAGAAGTTAAATGTTA-39; MHV SM
gene reverse (PM147), 59-AGAAAATCCAAGATACAC-39 [47].
In vitro kinase assay
For TBK1 kinase assays, HEK293T (in 35 mm plates) or MEF
cells (in 10 cm plates) were transfected with plasmids (HEK293T
cells 0.8 mg, MEF cells 8 mg) expressing Flag-tagged TBK1 or its
kinase dead mutant TBK1-K38A, in the presence of Myc-tagged
PLP2 or its C106A mutant (HEK293T cells 0.8 mg, MEF cells
8 mg). TBK1 protein was immunoprecipitated from cell lysates
36 h after transfection with Flag antibody-absorbed beads. The
yielded beads were then mixed with purified GST-IRF3131–426
protein (1 mg) in 25 mL kinase assay buffer (25 mM HEPES
pH7.4, 1 mM DTT, 50 mM KCl, 2 mM MgCl2, 2 mM MnCl2,
10 mM NaF, 1 mM Na3VO4,2 5mM ATP, 0.2 mCi/mL c-
32P-
ATP). The reaction took place at 25uC for 30 min before boiled in
16SDS-PAGE loading dye for 5 min. Proteins were separated in
10% SDS-PAGE and phospho-proteins were analyzed by
autoradiography.
In vitro DUB assays
To produce PLP2 DUB, plasmids expression Myc-tagged PLP2
or its C106A mutant (1.6 mg) was first transiently expressed in
HEK293T cells (in 35 mm plates) followed by immunoprecipita-
tion to 20 mL Myc antibody-absorbed beads. Recombinant
human TBK1 (500 ng) was then incubated with PLP2 immobi-
lized beads in 25 mL DUB buffer (50 mM HEPES, pH 7.5,
50 mM KCl, 2 mM MgCl2, 1 mM DTT) at 37uC for 2 h. The
effect of PLP2 on deubiquitination of TBK1 was assessed by IB
with anti-Ub antibody. To detect the effect of PLP2 on the kinase
activity of TBK1, the reaction buffer was adjust to 30 mL kinase
assay buffer and purified GST-IRF3131–426 protein (1 mg) was
added to the system at 25uC for additional 30 min.
Supporting Information
Figure S1 MHV-A59 infection does not induce K63-
linked ubiquitination of TBK1. MEF cells in 10 cm plates
were transiently transfected with 24 mg HA-tagged ubiquitin K63
(HA-Ub-K63) expressing plasmids. At 24 h post transfection, cells
were infected with MHV-A59 (MOI=5) or SeV (HA titer 1:25).
At indicated time post infection, ubiquitination status of the
endogenous TBK1 was immunoblotted with anti-HA antibody
after immunoprecipitated by anti-TBK1 antibody (3 mg, IP:
TBK1). The whole cell lysates (WCL) was immunoblotted with
anti-HA antibody for ubiquitin expression and massive cellular
ubiquitination (HA), and anti-b-actin antibody for input. Im-
munobloting with phosphor-STAT1 specific antibodies showed
activation of TBK1 after viral infection for time indicated (p-
STAT1). Total RNA of infected cells was extracted and subjected
to RT-PCR with specific primers for MHV SM gene, SeV N gene,
and mouse b-actin to check the viability of viruses.
(TIF)
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